Exosomes: a new horizon in lung cancer

Drug Discovery Today

Volumn 22, Issue 6, 2017, Pages 927-936

  Vanni, Irene ^a   Alama, Angela ^a   Grossi, Francesco ^a   Dal Bello, Maria Giovanna ^a   Coco, Simona ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; MICRORNA;

CANCER RESEARCH; CELL COMMUNICATION; CELL ISOLATION; EXOSOME; HUMAN; LUNG CANCER; MULTICENTER STUDY (TOPIC); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROGNOSTIC ASSESSMENT; REVIEW; TREATMENT RESPONSE; ANIMAL; DRUG DELIVERY SYSTEM; GENETICS; LUNG TUMOR;

ANIMALS; CANCER VACCINES; DRUG DELIVERY SYSTEMS; EXOSOMES; HUMANS; LUNG NEOPLASMS; MICRORNAS;

EID: 85015808804     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2017.03.004     Document Type: Review

References (68)

1. Siegel, R.L., et al. Cancer statistics, 2016. CA Cancer J. Clin. 66 (2016), 7–30.
2. Benoite, M., The evolving locally advanced non-small cell lung cancer landscape: building on past evidence and experience. Crit. Rev. Oncol. Hematol. 96 (2015), 319–327.
3. Hirsch, F.R., New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet 388 (2016), 1012–1024.
4. Heerink, W.J., Complication rates of CT-guided transthoracic lung biopsy: meta-analysis. Eur. Radiol. 27 (2016), 138–148.
5. Pérez-Callejo, D., Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring. Transl. Lung Cancer Res. 5 (2016), 455–465.
6. Yáñez-Mó, M., Biological properties of extracellular vesicles and their physiological functions. J. Extracell. Vesicles 4 (2015), 1–60.
7. Marcus, M.E., FedExosomes: engineering therapeutic biological nanoparticles that truly deliver. Pharmaceuticals 6 (2013), 659–680.
8. van der Pol, E., Classification, functions, and clinical relevance of extracellular vesicles. Pharmacol. Rev. 64 (2012), 676–705.
9. Harding, C., Endocytosis and intracellular processing of transferrin and colloidal gold-transferrin in rat reticulocytes: demonstration of a pathway for receptor shedding. Eur. J. Cell Biol. 35 (1984), 256–263.
10. Pan, B.T., Electron microscopic evidence for externalization of the transferrin receptor in vesicular form in sheep reticulocytes. J. Cell Biol. 101 (1985), 942–948.
11. Johnstone, R.M., Vesicle formation during reticulocyte maturation: Association of plasma membrane activities with released vesicles (exosomes). J. Biol. Chem. 262 (1987), 9412–9420.
12. Ventimiglia, L.N., Alonso, M.A., Biogenesis and function of T cell-derived exosomes. Front. Cell Dev. Biol., 4, 2016, 84.
13. Van Niel, G., Intestinal epithelial exosomes carry MHC class II/peptides able to inform the immune system in mice. Gut 52 (2003), 1690–1697.
14. Zhan, R., Heat shock protein 70 is secreted from endothelial cells by a non-classical pathway involving exosomes. Biochem. Biophys. Res. Commun. 387 (2009), 229–233.
15. Witwer, K.W., Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J. Extracell. Vesicles 2 (2013), 1–25.
16. Keerthikumar, S., ExoCarta: a web-based compendium of exosomal cargo. J. Mol. Biol. 428 (2016), 688–692.
17. Kalra, H., et al. Vesiclepedia: a compendium for extracellular vesicles with continuous community annotation. PLoS Biol., 2012, 10.1371/journal.pbio.1001450.
18. Kim, D.K., et al. EVpedia: an integrated database of high-throughput data for systemic analyses of extracellular vesicles. J. Extracell. Vesicles, 2013, 10.3402/jev.v2i0.20384.
19. Taylor, D.D., Shah, S., Methods of isolating extracellular vesicles impact down-stream analyses of their cargoes. Methods 87 (2015), 3–10.
20. Baranyai, T., et al. Isolation of exosomes from blood plasma: qualitative and quantitative comparison of ultracentrifugation and size exclusion chromatography methods. PLoS One, 2015, 10.1371/journal.pone.0145686.
21. Livshits, M.A., Isolation of exosomes by differential centrifugation: theoretical analysis of a commonly used protocol. Sci. Rep., 5, 2016, 17319.
22. Yuana, Y., et al. Co-isolation of extracellular vesicles and high-density lipoproteins using density gradient ultracentrifugation. J. Extracell. Vesicles, 2014, 10.3402/jev.v3.23262.
23. Kalra, H., Comparative proteomics evaluation of plasma exosome isolation techniques and assessment of the stability of exosomes in normal human blood plasma. Proteomics 13 (2013), 3354–3364.
24. Tauro, B.J., Comparison of ultracentrifugation, density gradient separation, and immunoaffinity capture methods for isolating human colon cancer cell line LIM1863-derived exosomes. Methods 56 (2012), 293–304.
25. Momen-Heravi, F., Current methods for the isolation of extracellular vesicles. Biol. Chem. 394 (2013), 1253–1262.
26. Jia, S., Emerging technologies in extracellular vesicle-based molecular diagnostics. Expert Rev. Mol. Diagn. 14 (2014), 307–321.
27. Böing, A.N., et al. Single-step isolation of extracellular vesicles by size-exclusion chromatography. J. Extracell. Vesicles, 2014, 10.3402/jev.v3.23430.
28. Gámez-Valero, A., et al. Size-exclusion chromatography-based isolation minimally alters extracellular vesicles’ characteristics compared to precipitating agents. Sci. Rep., 2016, 10.1038/srep33641.
29. Théry, C., et al. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr. Protoc. Cell Biol., 2006, 10.1002/0471143030.cb0322s30.
30. Rupp, A.K., Loss of EpCAM expression in breast cancer derived serum exosomes: role of proteolytic cleavage. Gynecol. Oncol. 122 (2011), 437–446.
31. Shao, Y., The functions and clinical applications of tumor-derived exosomes. Oncotarget 7 (2016), 60736–60751.
32. Bard, M.P., Proteomic analysis of exosomes isolated from human malignant pleural effusions. Am. J. Respir. Cell Mol. Biol. 31 (2004), 114–121.
33. Thakur, B.K., Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell Res. 24 (2014), 766–769.
34. Al-Nedawi, K., Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proc. Natl. Acad. Sci. U. S. A. 6 (2009), 3794–3799.
35. Park, J.O., Identification and characterization of proteins isolated from microvesicles derived from human lung cancer pleural effusions. Proteomics 13 (2013), 2125–2134.
36. Huang, S.H., Epidermal growth factor receptor-containing exosomes induce tumor-specific regulatory T cells. Cancer Invest. 31 (2013), 330–335.
37. Rahman, M.A., et al. Lung cancer exosomes as drivers of epithelial mesenchymal transition. Oncotarget, 2016, 10.18632/oncotarget.10243.
38. Xiao, X., Exosomes: decreased sensitivity of lung cancer A549 cells to cisplatin. PLoS One, 9, 2014, e89534.
39. Choi, D.Y., Extracellular vesicles shed from gefitinib-resistant nonsmall cell lung cancer regulate the tumor microenvironment. Proteomics 14 (2014), 1845–1856.
40. Li, X.Q., Exosomes derived from gefitinib-treated EGFR-mutant lung cancer cells alter cisplatin sensitivity via up-regulating autophagy. Oncotarget 7 (2016), 24585–24595.
41. Jung, J.H., Phospholipids of tumor extracellular vesicles stratify gefitinib-resistant nonsmall cell lung cancer cells from gefitinib-sensitive cells. Proteomics 15 (2015), 824–835.
42. Jakobsen, K.R., et al. Exosomal proteins as potential diagnostic markers in advanced non-small cell lung carcinoma. J. Extracell. Vesicles, 2015, 10.3402/jev.v4.26659.
43. Sandfeld-Paulsen, B., Exosomal proteins as diagnostic biomarkers in lung cancer. J. Thorac. Oncol. 11 (2016), 1701–1710.
44. Bartel, D.P., MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116 (2004), 281–297.
45. Li, M., MicroRNAs: control and loss of control in human physiology and disease. World J. Surg. 33 (2009), 667–684.
46. Chen, X., Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18 (2008), 997–1006.
47. Zandberga, E., Cell-free microRNAs as diagnostic, prognostic, and predictive biomarkers for lung cancer. Genes Chromosomes Cancer 52 (2013), 356–369.
48. Köberle, V., et al. Differential stability of cell-free circulating microRNAs: implications for their utilization as biomarkers. PLoS One, 2013, 10.1371/journal.pone.0075184.
49. Valadi, H., Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9 (2007), 654–659.
50. Sourvinou, I.S., Quantification of circulating miRNAs in plasma: effect of preanalytical and analytical parameters on their isolation and stability. J. Mol. Diagn. 15 (2013), 827–834.
51. Rabinowits, G., et al. Exosomal microRNA: a diagnostic marker for lung cancer. Clin. Lung Cancer 10 (2009), 42–46.
52. Yanaihara, N., Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9 (2006), 189–198.
53. Silva, J., Vesicle-related microRNAs in plasma of non-small cell lung cancer patients and correlation with survival. Eur. Respir. J. 37 (2011), 617–623.
54. Cazzoli, R., microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer. J. Thorac. Onco. 8 (2013), 1156–1162.
55. Rodríguez, M., Different exosome cargo from plasma/bronchoalveolar lavage in non-small-cell lung cancer. Genes Chromosomes Cancer 53 (2014), 713–724.
56. Munagala, R., Exosomal miRNAs as biomarkers of recurrent lung cancer. Tumour Biol. 37 (2016), 10703–10714.
57. Yang, M., High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer. Eur. J. Cancer 49 (2013), 604–615.
58. Tang, Y., et al. Erratum to: Radiation-induced miR-208a increases the proliferation and radioresistance by targeting p21 in human lung cancer cells. J. Exp. Clin. Cancer Res., 2016, 10.1186/s13046-016-0299-x.
59. Dinh, T.K., et al. Circulating miR-29a and miR-150 correlate with delivered dose during thoracic radiation therapy for non-small cell lung cancer. Radiat. Oncol., 2016, 10.1186/s13014-016-0636-4.
60. Kotmakçı, M., Extracellular vesicles as natural nanosized delivery systems for small-molecule drugs and genetic material: steps towards the future nanomedicines. J. Pharm. Pharm. Sci. 18 (2015), 396–413.
61. Smyth, T., et al. Biodistribution and delivery efficiency of unmodified tumor-derived exosomes. J. Control. Release 199 (2015), 145–155.
62. Ha, D., Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges. Acta Pharm. Sin. B 6 (2016), 287–296.
63. Johnsen, K.B., A comprehensive overview of exosomes as drug delivery vehicles −endogenous nanocarriers for targeted cancer therapy. Biochim. Biophys. Acta 1846 (2014), 75–87.
64. Cortez, M.A., PDL1 regulation by p53 via miR-34. J. Natl. Cancer Inst., 108, 2015, djv303.
65. Thery, C., Membrane vesicles as conveyors of immune responses. Nat. Rev. Immunol. 9 (2009), 581–593.
66. Zitvogel, L., Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat. Med. 4 (1998), 594–600.
67. Morse, M.A., et al. A Phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J. Transl. Med., 2005, 10.1186/1479-5876-3-9.
68. Besse, B., et al. Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. Oncoimmunology, 2016, 10.1080/2162402x.2015.1071008.